Skip to main content
SpringerLink
Log in

Active Surveillance of the Small Renal Mass

  • Chapter
  • First Online:
Renal Cell Carcinoma

Part of the book series: Current Clinical Urology ((CCU))

Abstract

Increased abdominal imaging has led to the significant incidental detection of clinically localized renal tumors. While the gold standard remains surgical excision, no demonstrable improvement in cancer-specific mortality has been observed, implying that a proportion of small renal masses (SRMs) may be indolent tumors that do not require surgical intervention. As a result, active surveillance (AS) has emerged as an alternative management strategy in select elderly or comorbid patients with significant competing risks. Although the contemporary literature characterizing the natural history of untreated renal tumors is limited, recent data demonstrate that the majority of SRMs demonstrate slow growth kinetics with low rates of metastatic progression while under observation. Prospective trials are necessary to define entry and intervention criteria for contemporary AS protocols.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277–300.

    Article  PubMed  Google Scholar 

  2. Chow WH, Devesa SS, Warren JL, et al. Rising incidence of renal cell cancer in the United States. JAMA. 1999;281(17):1628–31.

    Article  PubMed  CAS  Google Scholar 

  3. Hollingsworth JM, Miller DC, Daignault S, et al. Rising incidence of small renal masses: a need to reassess treatment effect. J Natl Cancer Inst. 2006;98(18):1331–4.

    Article  PubMed  Google Scholar 

  4. Cooperberg MR, Mallin K, Ritchey J, et al. Decreasing size at diagnosis of stage 1 renal cell carcinoma: analysis from the National Cancer Data Base, 1993 to 2004. J Urol. 2008;179(6):2131–5.

    Article  PubMed  Google Scholar 

  5. Kane CJ, Mallin K, Ritchey J, et al. Renal cell cancer stage migration: analysis of the National Cancer Data Base. Cancer. 2008;113(1):78–83.

    Article  PubMed  Google Scholar 

  6. Jayson M, Sanders H. Increased incidence of serendipitously discovered renal cell carcinoma. Urology. 1998;51(2):203–5.

    Article  PubMed  CAS  Google Scholar 

  7. Kutikov A, Fossett LK, Ramchandani P, et al. Incidence of benign pathologic findings at partial nephrectomy for solitary renal mass presumed to be renal cell carcinoma on preoperative imaging. Urology. 2006;68(4):737–40.

    Article  PubMed  Google Scholar 

  8. Crispen PL, Boorjian SA, Lohse CM, et al. Outcomes following partial nephrectomy by tumor size. J Urol. 2008;180(5):1912–7.

    Article  PubMed  Google Scholar 

  9. Remzi M, Ozsoy M, Klingler HC, et al. Are small renal tumors harmless? Analysis of histopathological features according to tumors 4 cm or less in diameter. J Urol. 2006;176(3):896–9.

    Article  PubMed  Google Scholar 

  10. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58(2):71–96.

    Article  PubMed  Google Scholar 

  11. Hollenbeck BK, Taub DA, Miller DC, et al. National utilization trends of partial nephrectomy for renal cell carcinoma: a case of underutilization? Urology. 2006;67(2):254–9.

    Article  PubMed  Google Scholar 

  12. Huang WC, Levey AS, Serio AM, et al. Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study. Lancet Oncol. 2006;7(9):735–40.

    Article  PubMed  Google Scholar 

  13. McKiernan J, Simmons R, Katz J, et al. Natural history of chronic renal insufficiency after partial and radical nephrectomy. Urology. 2002;59(6):816–20.

    Article  PubMed  Google Scholar 

  14. Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351(13): 1296–305.

    Article  PubMed  CAS  Google Scholar 

  15. Huang WC, Elkin EB, Levey AS, et al. Partial nephrectomy versus radical nephrectomy in patients with small renal tumors – is there a difference in mortality and cardiovascular outcomes? J Urol. 2009;181(1): 55–61 [discussion 2].

    Article  PubMed  Google Scholar 

  16. Thompson RH, Boorjian SA, Lohse CM, et al. Radical nephrectomy for pT1a renal masses may be associated with decreased overall survival compared with partial nephrectomy. J Urol. 2008;179(2):468–71 [discussion 72–3].

    Article  PubMed  Google Scholar 

  17. Gill IS, Kavoussi LR, Lane BR, et al. Comparison of 1,800 laparoscopic and open partial nephrectomies for single renal tumors. J Urol. 2007;178(1):41–6.

    Article  PubMed  Google Scholar 

  18. Lane BR, Gill IS. 7-Year oncological outcomes after laparoscopic and open partial nephrectomy. J Urol. 2010;183(2):473–9.

    Article  PubMed  Google Scholar 

  19. Scoll BJ, Uzzo RG, Chen DY, et al. Robot-assisted partial nephrectomy: a large single-institutional experience. Urology. 2010;75(6):1328–34.

    Article  PubMed  Google Scholar 

  20. Campbell SC, Novick AC, Belldegrun A, et al. Guideline for management of the clinical T1 renal mass. J Urol. 2009;182(4):1271–9.

    Article  PubMed  Google Scholar 

  21. Kutikov A, Kunkle DA, Uzzo RG. Focal therapy for kidney cancer: a systematic review. Curr Opin Urol. 2009;19(2):148–53.

    Article  PubMed  Google Scholar 

  22. Kunkle DA, Egleston BL, Uzzo RG. Excise, ablate or observe: the small renal mass dilemma – a meta-analysis and review. J Urol. 2008;179(4):1227–33 [discussion 33–4].

    Article  PubMed  Google Scholar 

  23. Kutikov A, Egleston BL, Wong YN, et al. Evaluating overall survival and competing risks of death in patients with localized renal cell carcinoma using a comprehensive nomogram. J Clin Oncol. 2010;28(2): 311–7.

    Article  PubMed  Google Scholar 

  24. Welch HG, Black WC. Overdiagnosis in cancer. J Natl Cancer Inst. 2010;102(9):605–13.

    Article  PubMed  Google Scholar 

  25. Dall’Era MA, Cooperberg MR, Chan JM, et al. Active surveillance for early-stage prostate cancer: review of the current literature. Cancer. 2008;112(8):1650–9.

    Article  PubMed  Google Scholar 

  26. Klotz L, Zhang L, Lam A, et al. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol. 2010;28(1):126–31.

    Article  PubMed  Google Scholar 

  27. Frank I, Blute ML, Cheville JC, et al. Solid renal tumors: an analysis of pathological features related to tumor size. J Urol. 2003;170(6 Pt 1):2217–20.

    Article  PubMed  Google Scholar 

  28. Thompson RH, Kurta JM, Kaag M, et al. Tumor size is associated with malignant potential in renal cell carcinoma cases. J Urol. 2009;181(5):2033–6.

    Article  PubMed  Google Scholar 

  29. Rothman J, Egleston B, Wong YN, et al. Histopathological characteristics of localized renal cell carcinoma correlate with tumor size: a SEER analysis. J Urol. 2009;181(1):29–33 [discussion 4].

    Article  PubMed  Google Scholar 

  30. Kunkle DA, Crispen PL, Li T, et al. Tumor size predicts synchronous metastatic renal cell carcinoma: implications for surveillance of small renal masses. J Urol. 2007;177(5):1692–6 [discussion 7].

    Article  PubMed  Google Scholar 

  31. Nguyen MM, Gill IS. Effect of renal cancer size on the prevalence of metastasis at diagnosis and mortality. J Urol. 2009;181(3):1020–7 [discussion 7].

    Article  PubMed  Google Scholar 

  32. Thompson RH, Hill JR, Babayev Y, et al. Metastatic renal cell carcinoma risk according to tumor size. J Urol. 2009;182(1):41–5.

    Article  PubMed  Google Scholar 

  33. Duffey BG, Choyke PL, Glenn G, et al. The relationship between renal tumor size and metastases in patients with von Hippel–Lindau disease. J Urol. 2004;172(1):63–5.

    Article  PubMed  Google Scholar 

  34. Frank I, Blute ML, Cheville JC, et al. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J Urol. 2002;168(6):2395–400.

    Article  PubMed  Google Scholar 

  35. Karakiewicz PI, Briganti A, Chun FK, et al. Multi-institutional validation of a new renal cancer-specific survival nomogram. J Clin Oncol. 2007;25(11): 1316–22.

    Article  PubMed  Google Scholar 

  36. Kattan MW, Reuter V, Motzer RJ, et al. A postoperative prognostic nomogram for renal cell carcinoma. J Urol. 2001;166(1):63–7.

    Article  PubMed  CAS  Google Scholar 

  37. Kim HL, Seligson D, Liu X, et al. Using tumor markers to predict the survival of patients with metastatic renal cell carcinoma. J Urol. 2005;173(5):1496–501.

    Article  PubMed  CAS  Google Scholar 

  38. Kim HL, Seligson D, Liu X, et al. Using protein expressions to predict survival in clear cell renal ­carcinoma. Clin Cancer Res. 2004;10(16):5464–71.

    Article  PubMed  CAS  Google Scholar 

  39. Patard JJ, Leray E, Rioux-Leclercq N, et al. Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. J Clin Oncol. 2005;23(12):2763–71.

    Article  PubMed  Google Scholar 

  40. Thompson RH, Leibovich BC, Lohse CM, et al. Dynamic outcome prediction in patients with clear cell renal cell carcinoma treated with radical nephrectomy: the D-SSIGN score. J Urol. 2007;177(2):477–80.

    Article  PubMed  Google Scholar 

  41. Zisman A, Pantuck AJ, Dorey F, et al. Mathematical model to predict individual survival for patients with renal cell carcinoma. J Clin Oncol. 2002;20(5):1368–74.

    Article  PubMed  Google Scholar 

  42. Zisman A, Pantuck AJ, Dorey F, et al. Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol. 2001;19(6):1649–57.

    PubMed  CAS  Google Scholar 

  43. Zisman A, Pantuck AJ, Wieder J, et al. Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J Clin Oncol. 2002;20(23):4559–66.

    Article  PubMed  Google Scholar 

  44. Cindolo L, Patard JJ, Chiodini P, et al. Comparison of predictive accuracy of four prognostic models for nonmetastatic renal cell carcinoma after nephrectomy: a multicenter European study. Cancer. 2005;104(7):1362–71.

    Article  PubMed  Google Scholar 

  45. Cindolo L, de la Taille A, Messina G, et al. A preoperative clinical prognostic model for non-metastatic renal cell carcinoma. BJU Int. 2003;92(9):901–5.

    Article  PubMed  CAS  Google Scholar 

  46. Raj GV, Thompson RH, Leibovich BC, et al. Preoperative nomogram predicting 12-year probability of metastatic renal cancer. J Urol. 2008;179(6):2146–51 [discussion 51].

    Article  PubMed  Google Scholar 

  47. Yaycioglu O, Roberts WW, Chan T, et al. Prognostic assessment of nonmetastatic renal cell carcinoma: a clinically based model. Urology. 2001;58(2):141–5.

    Article  PubMed  CAS  Google Scholar 

  48. Van Poppel H, Da Pozzo L, Albrecht W, et al. A Prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. Eur Urol. 2011;59:543–52.

    Article  PubMed  Google Scholar 

  49. Lane BR, Abouassaly R, Gao T, et al. Active treatment of localized renal tumors may not impact overall survival in patients aged 75 years or older. Cancer. 2010;116(13):3119–26.

    Article  PubMed  Google Scholar 

  50. Santos Arrontes D, Fernandez Acenero MJ, Garcia Gonzalez JI, et al. Survival analysis of clear cell renal carcinoma according to the Charlson comorbidity index. J Urol. 2008;179(3):857–61.

    Article  PubMed  Google Scholar 

  51. Hollingsworth JM, Miller DC, Daignault S, et al. Five-year survival after surgical treatment for kidney cancer: a population-based competing risk analysis. Cancer. 2007;109(9):1763–8.

    Article  PubMed  Google Scholar 

  52. Lughezzani G, Sun M, Budaus L, et al. Population-based external validation of a competing-risks nomogram for patients with localized renal cell carcinoma. J Clin Oncol. 2010;28(18):e299–300 [author reply e1].

    Article  PubMed  Google Scholar 

  53. Kutikov A, Egleston BL, Smaldone MC, et al. Quantification of competing risks of death with localized renal cell carcinoma (RCC): a comprehensive nomogram incorporating co-morbidities. In: Podium presentation; American Urologic Association meeting, Washington; 2011.

    Google Scholar 

  54. Uzzo RG. Renal masses – to treat or not to treat? If that is the question are contemporary biomarkers the answer? J Urol. 2008;180(2):433–4.

    Article  PubMed  Google Scholar 

  55. Jeldres C, Sun M, Liberman D, et al. Can renal mass biopsy assessment of tumor grade be safely substituted for by a predictive model? J Urol. 2009;182(6):2585–9.

    Article  PubMed  Google Scholar 

  56. Lane BR, Babineau D, Kattan MW, et al. A preoperative prognostic nomogram for solid enhancing renal tumors 7 cm or less amenable to partial nephrectomy. J Urol. 2007;178(2):429–34.

    Article  PubMed  Google Scholar 

  57. Crispen PL, Blute ML. Do percutaneous renal tumor biopsies at initial presentation affect treatment strategies? Eur Urol. 2009;55(2):307–9.

    Article  PubMed  Google Scholar 

  58. Lane BR, Samplaski MK, Herts BR, et al. Renal mass biopsy – a renaissance? J Urol. 2008;179(1):20–7.

    Article  PubMed  Google Scholar 

  59. Wang R, Wolf Jr JS, Wood Jr DP, et al. Accuracy of percutaneous core biopsy in management of small renal masses. Urology. 2009;73(3):586–90 [discussion 90–1].

    Article  PubMed  Google Scholar 

  60. Neuzillet Y, Lechevallier E, Andre M, et al. Accuracy and clinical role of fine needle percutaneous biopsy with computerized tomography guidance of small (less than 4.0 cm) renal masses. J Urol. 2004;171(5): 1802–5.

    Article  PubMed  Google Scholar 

  61. Lechevallier E, Andre M, Barriol D, et al. Fine-needle percutaneous biopsy of renal masses with helical CT guidance. Radiology. 2000;216(2):506–10.

    PubMed  CAS  Google Scholar 

  62. Tsui KH, Shvarts O, Smith RB, et al. Prognostic indicators for renal cell carcinoma: a multivariate analysis of 643 patients using the revised 1997 TNM staging criteria. J Urol. 2000;163(4):1090–5 [quiz 295].

    Article  PubMed  CAS  Google Scholar 

  63. Leveridge M, Shiff D, Chung H, et al. Small renal mass needle core biopsy: outcomes of non-diagnostic percutaneous biopsy and role of repeat biopsy (abstract 821). J Urol. 2010;183(4):e321.

    Article  Google Scholar 

  64. Blumenfeld AJ, Guru K, Fuchs GJ, et al. Percutaneous biopsy of renal cell carcinoma underestimates nuclear grade. Urology. 2010;76(3):610–3.

    Article  PubMed  Google Scholar 

  65. Khan AA, Shergill IS, Quereshi S, et al. Percutaneous needle biopsy for indeterminate renal masses: a national survey of UK consultant urologists. BMC Urol. 2007;7:10.

    Article  PubMed  Google Scholar 

  66. Wood BJ, Khan MA, McGovern F, et al. Imaging guided biopsy of renal masses: indications, accuracy and impact on clinical management. J Urol. 1999;161(5):1470–4.

    Article  PubMed  CAS  Google Scholar 

  67. Maturen KE, Nghiem HV, Caoili EM, et al. Renal mass core biopsy: accuracy and impact on clinical management. AJR Am J Roentgenol. 2007;188(2): 563–70.

    Article  PubMed  Google Scholar 

  68. Jewett MA, Zuniga A. Renal tumor natural history: the rationale and role for active surveillance. Urol Clin North Am. 2008;35(4):627–34. vii.

    Article  PubMed  Google Scholar 

  69. Rothman J, Crispen PL, Wong YN, et al. Pathologic concordance of sporadic synchronous bilateral renal masses. Urology. 2008;72(1):138–42.

    Article  PubMed  Google Scholar 

  70. Visapaa H, Bui M, Huang Y, et al. Correlation of Ki-67 and gelsolin expression to clinical outcome in renal clear cell carcinoma. Urology. 2003;61(4):845–50.

    Article  PubMed  Google Scholar 

  71. Delahunt B, Bethwaite PB, Thornton A, et al. Proliferation of renal cell carcinoma assessed by fixation-resistant polyclonal Ki-67 antibody labeling. Correlation with clinical outcome. Cancer. 1995;75(11):2714–9.

    Article  PubMed  CAS  Google Scholar 

  72. Shiina H, Igawa M, Urakami S, et al. Clinical significance of immunohistochemically detectable p53 protein in renal cell carcinoma. Eur Urol. 1997;31(1):73–80.

    PubMed  CAS  Google Scholar 

  73. Shvarts O, Seligson D, Lam J, et al. p53 is an independent predictor of tumor recurrence and progression after nephrectomy in patients with localized renal cell carcinoma. J Urol. 2005;173(3):725–8.

    Article  PubMed  CAS  Google Scholar 

  74. Zhang X, Takenaka I. Cell proliferation and apoptosis with BCL-2 expression in renal cell carcinoma. Urology. 2000;56(3):510–5.

    Article  PubMed  CAS  Google Scholar 

  75. Tomisawa M, Tokunaga T, Oshika Y, et al. Expression pattern of vascular endothelial growth factor isoform is closely correlated with tumour stage and vascularisation in renal cell carcinoma. Eur J Cancer. 1999;35(1):133–7.

    Article  PubMed  CAS  Google Scholar 

  76. Bilim V, Yuuki K, Itoi T, et al. Double inhibition of XIAP and Bcl-2 axis is beneficial for retrieving sensitivity of renal cell cancer to apoptosis. Br J Cancer. 2008;98(5):941–9.

    Article  PubMed  CAS  Google Scholar 

  77. Hedberg Y, Davoodi E, Roos G, et al. Cyclin-D1 expression in human renal-cell carcinoma. Int J Cancer. 1999;84(3):268–72.

    Article  PubMed  CAS  Google Scholar 

  78. Sabo E, Miselevich I, Bejar J, et al. The role of vimentin expression in predicting the long-term outcome of patients with localized renal cell carcinoma. Br J Urol. 1997;80(6):864–8.

    Article  PubMed  CAS  Google Scholar 

  79. Tatokoro M, Saito K, Iimura Y, et al. Prognostic impact of postoperative C-reactive protein level in patients with metastatic renal cell carcinoma undergoing cytoreductive nephrectomy. J Urol. 2008;180(2): 515–9.

    Article  PubMed  CAS  Google Scholar 

  80. Bui MH, Seligson D, Han KR, et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res. 2003;9(2):802–11.

    PubMed  CAS  Google Scholar 

  81. Crispen PL, Boorjian SA, Lohse CM, et al. Predicting disease progression after nephrectomy for localized renal cell carcinoma: the utility of prognostic models and molecular biomarkers. Cancer. 2008;113(3): 450–60.

    Article  PubMed  Google Scholar 

  82. Fujimoto N, Sugita A, Terasawa Y, et al. Observations on the growth rate of renal cell carcinoma. Int J Urol. 1995;2(2):71–6.

    Article  PubMed  CAS  Google Scholar 

  83. Kato M, Suzuki T, Suzuki Y, et al. Natural history of small renal cell carcinoma: evaluation of growth rate, histological grade, cell proliferation and apoptosis. J Urol. 2004;172(3):863–6.

    Article  PubMed  Google Scholar 

  84. Oda T, Miyao N, Takahashi A, et al. Growth rates of primary and metastatic lesions of renal cell carcinoma. Int J Urol. 2001;8(9):473–7.

    Article  PubMed  CAS  Google Scholar 

  85. Oda T, Takahashi A, Miyao N, et al. Cell proliferation, apoptosis, angiogenesis and growth rate of incidentally found renal cell carcinoma. Int J Urol. 2003;10(1):13–8.

    Article  PubMed  Google Scholar 

  86. Hicks RJ, Ware RE, Lau EW. PET/CT: will it change the way that we use CT in cancer imaging? Cancer Imaging. 2006;6:S52–62.

    Article  PubMed  Google Scholar 

  87. Lawrentschuk N, Davis ID, Bolton DM, et al. Functional imaging of renal cell carcinoma. Nat Rev Urol. 2010;7(5):258–66.

    Article  PubMed  Google Scholar 

  88. Lawrentschuk N, Poon AM, Foo SS, et al. Assessing regional hypoxia in human renal tumours using 18 F-fluoromisonidazole positron emission tomography. BJU Int. 2005;96(4):540–6.

    Article  PubMed  Google Scholar 

  89. Lawrentschuk N, Poon AM, Scott AM. Fluorine-18 fluorothymidine: a new positron emission radioisotope for renal tumors. Clin Nucl Med. 2006;31(12): 788–9.

    Article  PubMed  Google Scholar 

  90. Oyama N, Okazawa H, Kusukawa N, et al. 11 C-Acetate PET imaging for renal cell carcinoma. Eur J Nucl Med Mol Imaging. 2009;36(3):422–7.

    Article  PubMed  Google Scholar 

  91. Divgi CR, Pandit-Taskar N, Jungbluth AA, et al. Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial. Lancet Oncol. 2007;8(4):304–10.

    Article  PubMed  CAS  Google Scholar 

  92. Uzzo RG, Russo P, Chen D, et al. The multicenter phase III redect trial: a comparative study of 124 I-girentuximab-PET/CT versus diagnostic CT for the pre-operative diagnosis of clear cell renal cell carcinoma (ccRCC) (late breaking abstract; AUA, San Francisco); 2010.

    Google Scholar 

  93. Schachter LR, Bach AM, Snyder ME, et al. The impact of tumour location on the histological subtype of renal cortical tumours. BJU Int. 2006;98(1):63–6.

    Article  PubMed  Google Scholar 

  94. Venkatesh R, Weld K, Ames CD, et al. Laparoscopic partial nephrectomy for renal masses: effect of tumor location. Urology. 2006;67(6):1169–74 [discussion 74].

    Article  PubMed  Google Scholar 

  95. Weizer AZ, Gilbert SM, Roberts WW, et al. Tailoring technique of laparoscopic partial nephrectomy to tumor characteristics. J Urol. 2008;180(4):1273–8.

    Article  PubMed  Google Scholar 

  96. Kutikov A, Uzzo RG. The R.E.N.A.L. nephrometry score: a comprehensive standardized system for quantitating renal tumor size, location and depth. J Urol. 2009;182(3):844–53.

    Article  PubMed  Google Scholar 

  97. Ficarra V, Novara G, Secco S, et al. Preoperative aspects and dimensions used for an anatomical (PADUA) classification of renal tumours in patients who are candidates for nephron-sparing surgery. Eur Urol. 2009;56(5):786–93.

    Article  PubMed  Google Scholar 

  98. Simmons MN, Ching CB, Samplaski MK, et al. Kidney tumor location measurement using the C index method. J Urol. 2010;183(5):1708–13.

    Article  PubMed  Google Scholar 

  99. Kutikov A, Manley BJ, Canter DJ, et al. Anatomical features of enhancing renal masses predict histology and grade – an analysis using nephrometry (AUA abstract no. 1238). J Urol. 2010;183(4):e479.

    Article  Google Scholar 

  100. Crispen PL, Viterbo R, Boorjian SA, et al. Natural history, growth kinetics, and outcomes of untreated clinically localized renal tumors under active surveillance. Cancer. 2009;115(13):2844–52.

    Article  PubMed  Google Scholar 

  101. Smaldone MC, Kutikov A, Canter DJ, et al. A critical analysis of active surveillance with delayed curative intent for the treatment of small renal masses. Podium presentation (#11); presented at the Society of Urologic Oncology; 2010.

    Google Scholar 

  102. Letourneau I, Ouimet D, Dumont M, et al. Renal replacement in end-stage renal disease patients over 75 years old. Am J Nephrol. 2003;23(2):71–7.

    Article  PubMed  CAS  Google Scholar 

  103. Bosniak MA, Birnbaum BA, Krinsky GA, et al. Small renal parenchymal neoplasms: further observations on growth. Radiology. 1995;197(3):589–97.

    PubMed  CAS  Google Scholar 

  104. Abou Youssif T, Kassouf W, Steinberg J, et al. Active surveillance for selected patients with renal masses: updated results with long-term follow-up. Cancer. 2007;110(5):1010–4.

    Article  PubMed  Google Scholar 

  105. Abouassaly R, Lane BR, Novick AC. Active surveillance of renal masses in elderly patients. J Urol. 2008;180(2):505–8 [discussion 8–9].

    Article  PubMed  Google Scholar 

  106. Beisland C, Hjelle KM, Reisaeter LA, et al. Observation should be considered as an alternative in management of renal masses in older and comorbid patients. Eur Urol. 2009;55(6):1419–27.

    Article  PubMed  Google Scholar 

  107. Fernando HS, Duvuru S, Hawkyard SJ. Conservative management of renal masses in the elderly: our experience. Int Urol Nephrol. 2007;39(1):203–7.

    Article  PubMed  Google Scholar 

  108. Kouba E, Smith A, McRackan D, et al. Watchful waiting for solid renal masses: insight into the natural history and results of delayed intervention. J Urol. 2007;177(2):466–70 [discussion 70].

    Article  PubMed  Google Scholar 

  109. Lamb GW, Bromwich EJ, Vasey P, et al. Management of renal masses in patients medically unsuitable for nephrectomy – natural history, complications, and outcome. Urology. 2004;64(5):909–13.

    Article  PubMed  Google Scholar 

  110. Matsuzaki M, Kawano Y, Morikawa H, et al. Conservative management of small renal tumors. Hinyokika Kiyo. 2007;53(4):207–11.

    PubMed  Google Scholar 

  111. Rosales JC, Haramis G, Moreno J, et al. Active surveillance for renal cortical neoplasms. J Urol. 2010;183(5):1698–702.

    Article  PubMed  Google Scholar 

  112. Sowery RD, Siemens DR. Growth characteristics of renal cortical tumors in patients managed by watchful waiting. Can J Urol. 2004;11(5):2407–10.

    PubMed  Google Scholar 

  113. Volpe A, Panzarella T, Rendon RA, et al. The natural history of incidentally detected small renal masses. Cancer. 2004;100(4):738–45.

    Article  PubMed  Google Scholar 

  114. Wehle MJ, Thiel DD, Petrou SP, et al. Conservative management of incidental contrast-enhancing renal masses as safe alternative to invasive therapy. Urology. 2004;64(1):49–52.

    Article  PubMed  Google Scholar 

  115. Wong JA, Rendon RA. Progression to metastatic disease from a small renal cell carcinoma prospectively followed with an active surveillance protocol. Can Urol Assoc J. 2007;1(2):120–2.

    PubMed  Google Scholar 

  116. Mues AC, Landman J. Small renal masses: current concepts regarding the natural history and reflections on the American Urological Association guidelines. Curr Opin Urol. 2010;20(2):105–10.

    Article  PubMed  Google Scholar 

  117. Ozono S, Miyao N, Igarashi T, et al. Tumor doubling time of renal cell carcinoma measured by CT: collaboration of Japanese Society of Renal Cancer. Jpn J Clin Oncol. 2004;34(2):82–5.

    Article  PubMed  Google Scholar 

  118. Chawla SN, Crispen PL, Hanlon AL, et al. The natural history of observed enhancing renal masses: meta-analysis and review of the world literature. J Urol. 2006;175(2):425–31.

    Article  PubMed  Google Scholar 

  119. Siu W, Hafez KS, Johnston 3rd WK, et al. Growth rates of renal cell carcinoma and oncocytoma under surveillance are similar. Urol Oncol. 2007;25(2):115–9.

    Article  PubMed  Google Scholar 

  120. Crispen PL, Wong YN, Greenberg RE, et al. Predicting growth of solid renal masses under active surveillance. Urol Oncol. 2008;26(5):555–9.

    Article  PubMed  Google Scholar 

  121. Norton L. A Gompertzian model of human breast cancer growth. Cancer Res. 1988;48(24 Pt 1):7067–71.

    PubMed  CAS  Google Scholar 

  122. Mues AC, Haramis G, Badani K, et al. Active surveillance for larger (cT1bN0M0 and cT2N0M0) renal cortical neoplasms. Urology. 2010;76(3):620–3.

    Article  PubMed  Google Scholar 

  123. Neuzillet Y, Lechevallier E, Andre M, et al. Follow-up of renal oncocytoma diagnosed by percutaneous tumor biopsy. Urology. 2005;66(6):1181–5.

    Article  PubMed  Google Scholar 

  124. Crispen PL, Viterbo R, Fox EB, et al. Delayed intervention of sporadic renal masses undergoing active surveillance. Cancer. 2008;112(5):1051–7.

    Article  PubMed  Google Scholar 

  125. Kunkle DA, Crispen PL, Chen DY, et al. Enhancing renal masses with zero net growth during active surveillance. J Urol. 2007;177(3):849–53 [discussion 53–4].

    Article  PubMed  Google Scholar 

  126. Jewett MA, Finelli A, Morash C, et al. Active surveillance of small renal masses: a prospective multi-center Canadian uro-oncology group trial: abstract no. 896. J Urol. 2009;181(4 supplement):320.

    Article  Google Scholar 

  127. Crispen PL, Uzzo RG. The natural history of untreated renal masses. BJU Int. 2007;99(5 Pt B):1203–7.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. 123 Winchester Road, Merion Station, PA, 19066, USA

    Marc C. Smaldone

  2. Division of Urologic Oncology, Department of Surgical Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA, 19111, USA

    Marc C. Smaldone, Daniel Canter, Alexander Kutikov & Robert G. Uzzo

Authors
  1. Marc C. Smaldone
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Daniel Canter
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Alexander Kutikov
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Robert G. Uzzo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Robert G. Uzzo .

Editor information

Editors and Affiliations

  1. Glickman Urological and Kidney Institute, Center for Urologic Oncology, Cleveland Clinic, Cleveland, 44195, Ohio, USA

    Steven C. Campbell

  2. College of Medicine, Case Western Reserve University, Cleveland Clinic Lerner, Department of Solid Tumor Oncology, Cleveland, 44195, Ohio, USA

    Brian I. Rini

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media New York

About this chapter

Cite this chapter

Smaldone, M.C., Canter, D., Kutikov, A., Uzzo, R.G. (2013). Active Surveillance of the Small Renal Mass. In: Campbell, S., Rini, B. (eds) Renal Cell Carcinoma. Current Clinical Urology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-62703-062-5_10

Download citation

  • DOI: https://doi.org/10.1007/978-1-62703-062-5_10

  • Published:

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-62703-061-8

  • Online ISBN: 978-1-62703-062-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation